Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CD74 | P04233 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373231 | 0.83 | L3MBTL1 (0.68) | L3MBTL1HRH3HRH1HRH4SMN1; SMN2 | |
| SCHEMBL64435 | 0.83 | L3MBTL1 (0.68) | L3MBTL1HRH3HRH1HRH4SMN1; SMN2 | |
| SCHEMBL5807622 | 0.83 | ALDH1A1 (0.60) | L3MBTL1ESR1ESR2SMN1; SMN2LMNA | |
| SCHEMBL1772721 | 0.82 | CYP1A2 (0.56) | L3MBTL1ESR1ESR2HRH3HRH1 | |
| SCHEMBL31236458 | 0.81 | L3MBTL1 (0.66) | L3MBTL1HRH3HRH1HRH4SMN1; SMN2 | |
| SCHEMBL31276017 | 0.81 | L3MBTL1 (0.66) | L3MBTL1HRH3HRH1HRH4LMNA | |
| SCHEMBL29985764 | 0.81 | L3MBTL1 (0.66) | L3MBTL1HRH3HRH1HRH4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL31087535 | 0.81 | L3MBTL1 (0.71) | L3MBTL1HRH3HRH1HRH4LMNA | |
| Bromide SCHEMBL10759788 | 0.81 | L3MBTL1 (0.66) | L3MBTL1HRH3HRH1HRH4SMN1; SMN2 | |
| SCHEMBL30021715 | 0.81 | L3MBTL1 (0.66) | L3MBTL1HRH3HRH1HRH4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106750191-B | Sulfonated polyether ketone copolymers of the main chain containing pyridine groups, preparation method and application | 中国工程物理研究院化工材料研究所 | 2018-10-26 | — | — | CN | claimed |
| CN-106750191-A | Sulfonated polyether ketone copolymers, preparation method and application of the main chain containing pyridine groups | 中国工程物理研究院化工材料研究所 | 2017-05-31 | — | — | CN | claimed |
| CN-106750191-B | Sulfonated polyether ketone copolymers of the main chain containing pyridine groups, preparation method and application | 中国工程物理研究院化工材料研究所 | 2018-10-26 | — | — | CN | disclosed |
| CN-106750191-A | Sulfonated polyether ketone copolymers, preparation method and application of the main chain containing pyridine groups | 中国工程物理研究院化工材料研究所 | 2017-05-31 | — | — | CN | disclosed |
| CN-104854150-B | Activator compositions, their preparation, and their use in catalysts | 阿尔比马尔公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-103380154-B | Activator composition, its preparation and the purposes in catalysis thereof | 阿尔比马尔公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-104854150-A | Activator compositions, their preparation, and their use in catalysts | ALBEMARLE CORP | 2015-08-19 | — | — | CN | disclosed |
| US-20140186872-A1 | BISACODYL AND ITS ANALOGUES AS DRUGS FOR USE IN THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE- CNRS (FR) | 2014-07-03 | — | — | US | disclosed |
| US-20140186872-A1 | BISACODYL AND ITS ANALOGUES AS DRUGS FOR USE IN THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE- CNRS (FR) | 2014-07-03 | — | — | US | disclosed |
| US-8586755-B2 | Substituted nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2013-11-19 | — | — | US | disclosed |
| WO-2012168885-A2 | BISACODYL AND ANALOGUES AS DRUGS FOR TREATING CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2012-12-13 | — | — | WO | disclosed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| EP-1458375-A2 | COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| WO-2003051842-A2 | COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186872-A1 | BISACODYL AND ITS ANALOGUES AS DRUGS FOR USE IN THE TREATMENT OF CANCER | CCND1, DEGS1, MCL1 | L3MBTL1 499/4885ESR1 1880/4885ESR2 1851/4885 |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | LIPE, PNLIP, LPL | L3MBTL1 1427/4885ESR1 1412/4885ESR2 683/4885 |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | LIPE, PNLIP, LPL | L3MBTL1 2654/4885ESR1 890/4885ESR2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.